TABLE 2.
Efficacy outcomes from ACP-103-02030
| ENDPOINT | PLACEBO | PIMAVANSERIN 40mg | TREATMENT CHANGE | 95% CI (p-value) |
|---|---|---|---|---|
| SAPS-PD | -2.73 | -5.79 | -3.06 | -4.91 to -1.20 (p=0.0014) |
| CGI-I | 3.45 | 2.78 | -0.67 | -1.06 to -0.27 (p=0.0011) |
| CGI-S | -0.44 | -1.02 | -0.58 | -0.92 to -0.25 (p=0.007) |
| SCOPA-night | -0.49 | -1.42 | -0.93 | -1.84 to -0.02 (p=0.446) |
| SCOPA-day wake | -0.99 | -2.21 | -1.22 | -2.17 to -0.27 (p=0.0120) |
| Caregiver burden | 0.40 | -3.94 | -4.34 | -7.00 to -1.67 (p=0.0016) |
Abbreviations—SAPS-PD: Scale for Assessment of Positive Symptoms-Parkinson’s disease; CGI-I: Clinical Global Impression-Improvement; CGI-S: Clinical Global Impression-Severity; SCOPA: Scale for Outcomes of Parkinson’s Disease